Oncothyreon Inc (USA)  

(Public, NASDAQ:ONTY)   Watch this stock  
Find more results for ONTY
+0.01 (0.97%)
Real-time:   3:43PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.00 - 1.07
52 week 1.00 - 4.69
Open 1.00
Vol / Avg. 456,766.00/839,670.00
Mkt cap 94.08M
P/E     -
Div/yield     -
EPS -0.54
Shares 94.93M
Beta 1.59
Inst. own 66%
Mar 8, 2016
Q4 2015 Oncothyreon Inc Earnings Release (Estimated) Add to calendar
Dec 8, 2015
Oncothyreon to Discuss Clinical Data Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -17.41% -55.16%
Return on average equity -19.69% -61.37%
Employees 49 -
CDP Score - -


2601 4th Ave Ste 500
SEATTLE, WA 98121-3222
United States - Map
+1-206-8012100 (Phone)
+1-206-8012101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Oncothyreon Inc. (Oncothyreon) is a clinical-stage biopharmaceutical company focused primarily on the development of therapeutic products for the treatment of cancer. The Company's clinical-stage product candidates include ONT-380, an orally active and selective small-molecule HER2 inhibitor, and ONT-10, a therapeutic vaccine targeting the Mucin 1 peptide antigen. The Company is developing preclinical product candidates in oncology, and certain rare diseases, using its protocell technology. It also collaborates with partners to discover and develop additional product candidates. The Company is developing a series of orally active Chk1 inhibitors in collaboration with Sentinel Oncology Ltd. The Company is focusing its activities with protocells on the delivery of mini-circle DNA or mRNA to produce proteins intracellularly in specifically targeted organs or cells. It is collaborating with Adimab LLC for the discovery of antibodies against undisclosed immunotherapy targets in oncology.

Officers and directors

Christopher S. Henney Ph.D. Chairman of the Board, Interim Chief Executive Officer
Age: 74
Bio & Compensation  - Reuters
Julia Marie Eastland Chief Financial Officer, Vice President - Corporate Development, Secretary
Age: 49
Bio & Compensation  - Reuters
Gary W. Christianson Chief Operating Officer
Age: 60
Bio & Compensation  - Reuters
Jay Venkatesan M.D. Executive Vice President, General Manager
Age: 45
Bio & Compensation  - Reuters
Scott Peterson Ph.D. Chief Scientific Officer
Age: 53
Bio & Compensation  - Reuters
Diana Hausman M.D. Chief Medical Officer
Age: 51
Bio & Compensation  - Reuters
Gwendolyn A. Fyfe M.D. Director
Age: 63
Bio & Compensation  - Reuters
Mark Lampert Director
Bio & Compensation  - Reuters
Richard L. Jackson Ph.D. Independent Director
Age: 75
Bio & Compensation  - Reuters
Steven P. James Independent Director
Age: 57
Bio & Compensation  - Reuters